Integra LifeSciences (IART) vs NovoCure (NVCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Integra LifeSciences (IART) has outperformed NovoCure (NVCR) over the past year, gaining 10.0% versus a loss of 10.4%. Over five years, IART leads with a -79.6% price change compared with -89.0% for NVCR. NovoCure is the larger company by market cap ($1.25 billion vs $1.03 billion), about 1.2 times the size.
NovoCure converts more of its revenue into profit, with a net margin of -20.8% versus -31.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IART | NVCR |
|---|---|---|
| Share price | $13.25 | $10.71 |
| Market cap | $1.03B | $1.25B |
| 1-day change | -2.21% | +0.19% |
| YTD return | +6.68% | -17.17% |
| 1-year return | +10.05% | -10.38% |
| 5-year return | -79.57% | -88.96% |
| P/E ratio (TTM) | 77.94 | — |
| Forward P/E | 5.59 | — |
| EPS (TTM) | $0.17 | $-1.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.64B | $655.35M |
| Revenue growth (YoY) | +1.53% | +8.28% |
| Net income (latest FY) | $-516.47M | $-136.23M |
| Gross margin | 50.86% | 74.54% |
| Operating margin | -30.17% | -23.47% |
| Net margin | -31.58% | -20.79% |
| 52-week high | $20.49 | $21.45 |
| 52-week low | $8.70 | $9.82 |
| Distance from 52-week high | -35.33% | -50.07% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +18.26% | +144.07% |
| Average volume | 1.05M | 1.51M |
| Shares outstanding | 77.80M | 116.92M |
| Employees | 4,427 | 1,605 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IART has outperformed NVCR by 20.4 percentage points over the past year.
- NovoCure is more profitable, keeping -20.8 cents of every revenue dollar as net income versus -31.6 cents for Integra LifeSciences.
- NovoCure grew revenue faster in its latest fiscal year (+8.28% vs +1.53%).
About Integra LifeSciences
IART stock →Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments.
Health Care · Medical/Dental Instruments · 4,427 employees
About NovoCure
NVCR stock →NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
Health Care · Medical/Dental Instruments · 1,605 employees
IART vs NVCR FAQ
Which is bigger, Integra LifeSciences or NovoCure?
NovoCure (NVCR) is larger, with a market capitalization of $1.25B compared with $1.03B for Integra LifeSciences (IART).
Which stock has performed better over the past year, IART or NVCR?
IART returned +10.05% over the past 12 months, compared with -10.38% for NVCR (price return, excluding dividends). Past performance does not predict future results.
Are Integra LifeSciences and NovoCure in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.